CORE--PHARMACOLOGY CORE

核心--药理学核心

• 批准号: 6268506
• 负责人: JOSEPH Rocco BERTINO
• 金额: $ 18.22万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6268506
• 关键词: antineoplastics; biomedical facility; blood chemistry; capillary electrophoresis; clinical trials; diagnosis design /evaluation; dosage; drug metabolism; drug screening /evaluation; high performance liquid chromatography; human subject; pharmacokinetics

During the previous funding period, the pharmacology core laboratory has supported all three projects, providing measurement of more than a dozen different anticancer drugs. In the previous application the specific aims outlined pharmacology studies with hexamethylene bisacetamide; leucovorin, 5 fluorouracil, and 5 fluoro-2'-deoxyuridine; lometrexol; chloroquinoxaline sulfonamide(CQS), and trimetrexate. Each of these assays was developed and pharmacology studies completed. The analytical laboratory performed drug concentration analysis on more than 2000 samples annually. The contribution of the pharmacology core to the clinical development of all trans retinoic acid, suramin, and CQS have been particularly important. The specific aims for the pharmacology core laboratory will be: 1. To continue analytical support for ongoing studies of (CQS), edatrexate, taxol, and all trans retinoic acid (ATRA); 2. Assays for phenylacetic acid, phenylbutyric acid and phenyl acetylglutamine; 3. Develop a method for lobaplatin in human body fluids; 4. Develop assays for clinically important retinoids including All trans retinoic acid, 9-cis retinoic acid, 13 cis reinoic acid and novel retinoids proposed in Project 1; 5. Establish a method for measuring the P 450 test substrate, erythromycin, in plasma; 6. Develop a more sensitive HPLC assay which can specifically separate and quantitate antifolates including methotrexate, edatrexate, trimetrexate and newer antifols; 7. To employ capillary electrophoresis to develop a micro assay for methotrexate polyglutamates in small tissue samples.

在上一资助期内，药理学核心实验室已 支持所有三个项目，提供十多个测量 不同的抗癌药物。在之前的申请中，具体目标 概述了六亚甲基双乙酰胺的药理学研究；亚叶酸， 5氟尿嘧啶和5氟-2'-脱氧尿苷；洛美曲索； 氯喹喔啉磺酰胺（CQS）和三甲曲沙。这些测定中的每一个 已开发并完成药理学研究。分析性的 实验室对2000多个样品进行药物浓度分析 每年。药理学核心对临床的贡献 全反式视黄酸、苏拉明和 CQS 的开发已 特别重要。 药理学核心实验室的具体目标是： 1. 继续为正在进行的研究提供分析支持 (CQS)、edatrexate、 紫杉醇和全反式视黄酸（ATRA）； 2. 苯乙酸的测定 酸、苯基丁酸和苯基乙酰谷氨酰胺； 3. 制定方法 用于人体体液中的洛铂； 4. 开发临床检测方法 重要的类视黄醇，包括全反式视黄酸、9-顺式视黄酸 项目1提出的13顺式视黄酸、13顺式视黄酸和新型类维生素A； 5. 建立测定 P 450 测试底物红霉素、 在血浆中； 6. 开发一种更灵敏的 HPLC 检测方法，可以特异性地检测 分离和定量抗叶酸剂，包括甲氨蝶呤、依达曲沙、 三甲曲沙和更新的抗叶酸药； 7. 采用毛细管电泳法 开发小组织中甲氨蝶呤聚谷氨酸盐的微量测定 样品。